Evidence map›Paper›PMID 30689161›Full record

ArticleInfection2019

HBsAg-negative/anti-HBc-positive patients treated with rituximab: prophylaxis or monitoring to prevent hepatitis B reactivation?

Linda Drößler, Clara Lehmann, Karin Töpelt, Dirk Nierhoff, Jörg J Vehreschild, Jan Rybniker, Michael Hallek, Julia Fischer, Verena Stormberg, Gerd Fätkenheuer and 2 more

Abstract read
PubMed Publisher
In one paragraph

Article in Infection, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Linda DrößlerDepartment I of Internal Medicine, University of Cologne, Kerpener Straße 62, 50937, Cologne, Germany.
Clara LehmannDepartment I of Internal Medicine, University of Cologne, Kerpener Straße 62, 50937, Cologne, Germany.
Karin TöpeltDepartment I of Internal Medicine, University of Cologne, Kerpener Straße 62, 50937, Cologne, Germany.
Dirk NierhoffDepartment of Gastroenterology and Hepatology, University of Cologne, Cologne, Germany.
Jörg J VehreschildDepartment I of Internal Medicine, University of Cologne, Kerpener Straße 62, 50937, Cologne, Germany.
Jan RybnikerDepartment I of Internal Medicine, University of Cologne, Kerpener Straße 62, 50937, Cologne, Germany.
Michael HallekDepartment I of Internal Medicine, University of Cologne, Kerpener Straße 62, 50937, Cologne, Germany.
Julia FischerDepartment I of Internal Medicine, University of Cologne, Kerpener Straße 62, 50937, Cologne, Germany.
Verena StormbergInstitute of Pharmacy, University of Cologne, Cologne, Germany.
Gerd FätkenheuerDepartment I of Internal Medicine, University of Cologne, Kerpener Straße 62, 50937, Cologne, Germany.
Ulrike WielandInstitute of Virology, University of Cologne, Cologne, Germany.
Norma JungDepartment I of Internal Medicine, University of Cologne, Kerpener Straße 62, 50937, Cologne, Germany. norma.jung@uk-koeln.de.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Rituximab (RTX) has been classified as a drug associated with a high risk for hepatitis B virus (HBV) reactivation in HbsAg-negative/anti-HBc-positive patients. However, data on frequency of HBV reactivation are limited especially for RTX monotherapy. Several new recommendations for screening, monitoring and prophylactic antiviral treatment have been published recently. Here, we report the real-life experience in the management and reactivation rate of HbsAg-negative/anti-HBc-positive patients treated with RTX with or without chemotherapy from a large cohort and discuss our results in the light of updated recommendations.

Indexed as

AdultAgedAntirheumatic AgentsCohort StudiesDrug Therapy, CombinationFemaleGermanyHepatitis BHepatitis B Core AntigensHepatitis B Surface AntigensHepatitis B virusHumansMaleMiddle AgedRetrospective StudiesRituximabAntirheumatic AgentsHepatitis B Core AntigensHepatitis B Surface AntigensRituximabAutoimmune diseasesHematologic diseasesHepatitis BMonotherapyReactivationRisk groupsRituximab

Identifiers

PMID30689161

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.